An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PERFlexS
- Sponsors Janssen-Cilag
- 31 Aug 2018 Biomarkers information updated
- 29 Jun 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 23 Oct 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.